A Phase 2 Study to Evaluate Safety and Efficacy of AMB-05X in Subjects With Idiopathic Pulmonary Fibrosis
Status:
Not yet recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
AMB-053-01 is a randomized, placebo controlled, multicenter study which will enroll
approximately 36 subjects ages 40 and older with IPF for 6 doses over a 24-week dosing
period.